Related Experiment Video
Updated: Jun 6, 2026
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor
Naomi Ito-Habe1, Hideo Wada, Takeshi Matsumoto
1Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
Abstract:
Thrombotic microangiopathy (TMA) is associated with vascular endothelial cell injury and is sometimes linked with poor outcome. Von Willebrand factor (VWF) propeptide (VWFpp) is considered to be a marker of vascular endothelial cell injury. The plasma levels of VWF, VWFpp, and thrombomodulin (TM) were evaluated for their use in the diagnosis of TMA in 75 patients with TMA. There were 30 TMA patients with marked decreases in ADAMTS13 (TMA/ADAMTS13) and 45 without the decrease (TMA/other). The plasma levels of TM, VWF, and VWFpp values were significantly high in patients with TMA, especially TMA/other group. The plasma levels of TM and VWFpp were significantly high in non-survivor with TMA. In the TMA/other group, the plasma levels of VWFpp were negatively correlated with ADAMTS13 activity. The plasma levels of TM correlated with the renal function, but the plasma levels of VWFpp did not. A ROC analysis indicated that VWFpp and TM were useful markers for the prediction of a poor outcome. These findings suggest that VWFpp is an useful marker for the diagnosis of TMA and for the prediction of poor outcome.
Insights
Von Willebrand factor propeptide (VWFpp) aids in diagnosing thrombotic microangiopathy (TMA) and predicting poor outcomes. Elevated VWFpp and thrombomodulin (TM) levels indicate TMA severity and are linked to mortality.
Area of Science:
- Hematology
- Nephrology
- Vascular Biology
Background:
- Thrombotic microangiopathy (TMA) involves vascular endothelial cell injury and is often associated with poor prognosis.
- Von Willebrand factor propeptide (VWFpp) is recognized as a biomarker for endothelial cell injury.
Purpose of the Study:
- To evaluate the diagnostic and prognostic utility of plasma levels of Von Willebrand factor (VWF), VWF propeptide (VWFpp), and thrombomodulin (TM) in patients with TMA.
- To differentiate TMA based on ADAMTS13 activity levels and assess the correlation of biomarkers with clinical outcomes.
Main Methods:
- Plasma levels of VWF, VWFpp, and TM were measured in 75 TMA patients, categorized into TMA with decreased ADAMTS13 (TMA/ADAMTS13) and TMA of other causes (TMA/other).
- Statistical analyses, including correlation and ROC analysis, were performed to assess the relationship between biomarker levels, ADAMTS13 activity, renal function, and patient survival.
Main Results:
- Plasma levels of TM, VWF, and VWFpp were significantly elevated in TMA patients, particularly in the TMA/other group.
- Elevated TM and VWFpp levels were associated with non-survival in TMA patients.
- VWFpp levels negatively correlated with ADAMTS13 activity in the TMA/other group, while TM levels correlated with renal function.
Conclusions:
- VWFpp and TM are valuable biomarkers for the diagnosis of TMA and prediction of poor outcomes.
- VWFpp serves as a useful marker for TMA diagnosis and prognosis, especially in cases not primarily driven by ADAMTS13 deficiency.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:30Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
